Nascient Ltd was founded by Professor Midwood in 2012. The company's aims are to produce function blocking antibodies designed to inhibit the pro-inflammatory effects of extracellular matrix molecules such as tenascin-C. These antibodies have the potential to be developed as new biological therapeutics for the treatment of inflammatory diseases including rheumatoid arthritis.
My research involves testing the efficacy of these antibodies in different cell based and molecular assays, and in disease models of arthritis, and determining their underlying mode of action.
To WS. et al, (2015), Br J Pharmacol, 172, 3805 - 3816
Aungier SR. et al, (2015), Immunology, 144, 34 - 44